Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries

dc.authorid0000-0002-9517-1413
dc.authorid0000-0002-8022-5757
dc.authorid0000-0003-4776-5601
dc.authorid0000-0002-0121-9683
dc.authorid0000-0001-6384-2035
dc.authorid0000-0001-8166-1182
dc.authorid0000-0003-0190-8988
dc.contributor.authorRajan, Selina
dc.contributor.authorMcKee, Martin
dc.contributor.authorRangarajan, Sumathy
dc.contributor.authorBangdiwala, Shrikant
dc.contributor.authorRosengren, Annika
dc.contributor.authorGupta, Rajeev
dc.contributor.authorKutty, Vellappillil Raman
dc.date.accessioned2025-05-10T19:53:29Z
dc.date.issued2020
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractThis cohort study identifies associations between depressive symptoms and incident cardiovascular disease and all-cause mortality in countries at different levels of economic development and in urban and rural areas Importance Depression is associated with incidence of and premature death from cardiovascular disease (CVD) and cancer in high-income countries, but it is not known whether this is true in low- and middle-income countries and in urban areas, where most people with depression now live. Objective To identify any associations between depressive symptoms and incident CVD and all-cause mortality in countries at different levels of economic development and in urban and rural areas. Design, Setting, and Participants This multicenter, population-based cohort study was conducted between January 2005 and June 2019 (median follow-up, 9.3 years) and included 370 urban and 314 rural communities from 21 economically diverse countries on 5 continents. Eligible participants aged 35 to 70 years were enrolled. Analysis began February 2018 and ended September 2019. Exposures Four or more self-reported depressive symptoms from the Short-Form Composite International Diagnostic Interview. Main Outcomes and Measures Incident CVD, all-cause mortality, and a combined measure of either incident CVD or all-cause mortality. Results Of 145862 participants, 61235 (58%) were male and the mean (SD) age was 50.05 (9.7) years. Of those, 15983 (11%) reported 4 or more depressive symptoms at baseline. Depression was associated with incident CVD (hazard ratio [HR], 1.14; 95% CI, 1.05-1.24), all-cause mortality (HR, 1.17; 95% CI, 1.11-1.25), the combined CVD/mortality outcome (HR, 1.18; 95% CI, 1.11-1.24), myocardial infarction (HR, 1.23; 95% CI, 1.10-1.37), and noncardiovascular death (HR, 1.21; 95% CI, 1.13-1.31) in multivariable models. The risk of the combined outcome increased progressively with number of symptoms, being highest in those with 7 symptoms (HR, 1.24; 95% CI, 1.12-1.37) and lowest with 1 symptom (HR, 1.05; 95% CI, 0.92 -1.19; P for trend < .001). The associations between having 4 or more depressive symptoms and the combined outcome were similar in 7 different geographical regions and in countries at all economic levels but were stronger in urban (HR, 1.23; 95% CI, 1.13-1.34) compared with rural (HR, 1.10; 95% CI, 1.02-1.19) communities (P for interaction = .001) and in men (HR, 1.27; 95% CI, 1.13-1.38) compared with women (HR, 1.14; 95% CI, 1.06-1.23; P for interaction < .001). Conclusions and Relevance In this large, population-based cohort study, adults with depressive symptoms were associated with having increased risk of incident CVD and mortality in economically diverse settings, especially in urban areas. Improving understanding and awareness of these physical health risks should be prioritized as part of a comprehensive strategy to reduce the burden of noncommunicable diseases worldwide. Question Does the increased risk of incident cardiovascular disease and mortality in middle-aged adults with depressive symptoms vary across and within countries? Findings In this cohort study from 21 countries and 145862 participants, cardiovascular events and death increased by 20% in people with 4 or more depressive symptoms compared with people without. The relative risk increased in countries at all economic levels but was more than twice as high in urban than rural areas. Meaning Adults with depressive symptoms experience poor physical health outcomes and increased risk of mortality across the world and in different settings, especially in urban areas.
dc.description.sponsorshipMaryW. Burke endowed chair of the Heart and Stroke Foundation of Ontario; Population Health Research Institute; Hamilton Health Sciences Research Institute (HHSRI); Canadian Institutes of Health Research's Strategy for Patient Oriented Research, through Ontario SPOR Support Unit; Ontario Ministry of Health and Long-Term Care; AstraZeneca (Canada); Sanofi-Aventis (France); Sanofi-Aventis (Canada); Boehringer Ingelheim (Germany); Boehringer Ingelheim (Canada); Servier; GlaxoSmithKline; Argentina: Fundacion ECLA (Estudios Clinicos Latino America); Bangladesh: Independent University, Bangladesh; Bangladesh: Mitra and Associates; Brazil: Unilever Health Institute; Chile: Universidad de La Frontera [DI13-PE11]; China: National Center for Cardiovascular Diseases; China: ThinkTank Research Center for Health Development; Colombia: Colciencias [6566-04-18062, 6517-777-58228]; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia [100-IRDC/BIOTEK 16/6/21 [13/2007], 07-05-IFN-BPH 010]; Malaysia: Universiti Teknologi MARA; Malaysia: Universiti Kebangsaan Malaysia [UKM-Hejim-Komuniti-15-2010]; Occupied Palestinian Territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East; Philippines: Philippine Council for Health Research and Development; Poland: Polish Ministry of Science and Higher Education [290/W-PURE/2008/0]; Poland: Wroclaw Medical University; South Africa: The North-West University; South Africa: SA and Netherlands Programme for Alternative Development; South Africa: National Research Foundation; South Africa: Medical Research Council of South Africa; South Africa: The South Africa Sugar Association; South Africa: Faculty of Community and Health Sciences; Sweden: Swedish Heart and Lung Foundation; Sweden: Swedish Research Council; Sweden: Swedish Council for Health, Working Life andWelfare; Sweden: King Gustaf V and Queen Victoria Freemason's Foundation; Sweden: AFA Insurance; Turkey: Metabolic Syndrome Society; Turkey: AstraZeneca; Turkey: Sanofi Aventis; United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences; United Arab Emirates: Dubai Health Authority, Dubai; Dairy Farmers of Canada; National Dairy Council (US); Public Health Agency of Canada; Champlain Cardiovascular Disease Prevention Network; Saudi Arabia: Saudi Heart Association; Saudi Arabia: Saudi Gastroenterology Association; Saudi Arabia: Dr Mohammad Alfagih Hospital; Saudi Arabia: King Saud University; Occupied Palestinian Territory: International Development Research Centre (Canada); Malaysia: Ministry of Higher Education of Malaysia [600-RMI/LRGS/5/3 [2/2011]]; Canadian Institutes of Health Research; Heart and Stroke Foundation of Ontario; Novartis; King Pharma; [RG -1436-013]
dc.description.sponsorshipDr Yusuf is supported by the MaryW. Burke endowed chair of the Heart and Stroke Foundation of Ontario. The PURE study is an investigator-initiated study that is funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute (HHSRI), the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, support from Canadian Institutes of Health Research's Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit and the Philippines: Philippine Council for Health Research and Development; PolandOccupied Palestinian Territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, and International Development Research Centre (Canada); Philippines: Philippine Council for Health Research and Development; Poland: PoliUniversiti Kebangsaan Malaysia India: Indian Council of Medical Research; ThinkTank Research Center for Health Development;Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies with major contributions from AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GlaxoSmithKline and additional contributions from Novartis and King Pharma and from various national or local organizations in participating countries. These include: Argentina: Fundacion ECLA (Estudios Clinicos Latino America); Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute; Chile: Universidad de La Frontera (grant DI13-PE11); China: National Center for Cardiovascular Diseases and ThinkTank Research Center for Health Development; Colombia: Colciencias (grants 6566-04-18062 and 6517-777-58228); India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia (grant 100-IRDC/BIOTEK 16/6/21 [13/2007] and 07-05-IFN-BPH 010), Ministry of Higher Education of Malaysia (grant 600-RMI/LRGS/5/3 [2/2011]), Universiti Teknologi MARA, and Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); Occupied Palestinian Territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, and International Development Research Centre (Canada); Philippines: Philippine Council for Health Research and Development; Poland: Polish Ministry of Science and Higher Education (grant 290/W-PURE/2008/0), Wroclaw Medical University; Saudi Arabia: Saudi Heart Association, Saudi Gastroenterology Association, Dr Mohammad Alfagih Hospital, The Deanship of Scientific Research at King Saud University, and Riyadh, Saudi Arabia (research group RG -1436-013); South Africa: The North-West University, SA and Netherlands Programme for Alternative Development, National Research Foundation, Medical Research Council of South Africa, The South Africa Sugar Association, and Faculty of Community and Health Sciences; Sweden: grants from the Swedish state under the agreement concerning research and education of doctors; the Swedish Heart and Lung Foundation; the Swedish Research Council; the Swedish Council for Health, Working Life andWelfare, King Gustaf V and Queen Victoria Freemason's Foundation, and AFA Insurance; Turkey: Metabolic Syndrome Society, AstraZeneca, and Sanofi Aventis; United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai. r r This study was also supported by an unrestricted grant from Dairy Farmers of Canada and the National Dairy Council (US), Public Health Agency of Canada, and Champlain Cardiovascular Disease Prevention Network.
dc.identifier.doi10.1001/jamapsychiatry.2020.1351
dc.identifier.endpage1063
dc.identifier.issn2168-622X
dc.identifier.issn2168-6238
dc.identifier.issue10
dc.identifier.pmid32520341
dc.identifier.scopus2-s2.0-85087027449
dc.identifier.scopusqualityQ1
dc.identifier.startpage1052
dc.identifier.urihttps://doi.org/10.1001/jamapsychiatry.2020.1351
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12752
dc.identifier.volume77
dc.identifier.wosWOS:000582383300013
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAmer Medical Assoc
dc.relation.ispartofJama Psychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectAcute Myocardial-Infarction
dc.subjectWorld-Health-Organization
dc.subjectMental-Disorders
dc.subjectFollow-Up
dc.subjectHeart-Failure
dc.subjectCancer-Risk
dc.subjectUrbanization
dc.subjectMetaanalysis
dc.subjectPrevalence
dc.subjectMechanisms
dc.titleAssociation of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
12752.pdf
Boyut:
248.95 KB
Biçim:
Adobe Portable Document Format